Puma Biotechnology (PBYI) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.20
- Estimate
- $0.07
- Surprise
- +185.7%
- Revenue (period 2026-06-30)
- $56.5M
- Score at report (before → after)
- 5.1 → 5.1/10
Revenue source: xbrl.
How the report landed
Puma Biotechnology (PBYI) beat the $0.07 estimate with adjusted EPS of $0.20 — a large 185.7% upside surprise. TrendMatrix's engine moved from Hold (5.1/10) to Buy (Wait) at 5.1/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PBYI Buy (Wait) at 6.0/10.
4 of the last 4 quarters beat the estimate; this quarter's +185.7% surprise compares with a +103.6% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.5 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: NERLYNX
- Earnings in 7 days (event risk)
- EARNINGS_PROXIMITY:7d<=7d
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $10.62
- Entry target
- $9.77
- Price target
- $11.27
- Stop
- $9.09
- Upside to target
- +6.1%
Forward estimates sit below the trailing run-rate (30.3× forward vs 20.8× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
PBYI at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $548.2M
- P/E (fwd)
- 30.3
- P/E (ttm)
- 20.8
- 52-week range
- $4.58–$11.50
- Off 52-week high
- 7.7%
- RSI (14)
- 59
- Volume vs avg
- 1.12×
- Score today
- 6.0/10